Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Perphenazine

FDA-approved product (tablet, oral), marketed as Perphenazine, Trilafon.

Registered studies
34
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Perphenazine
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Nausea and vomiting
  • Psychosis
  • Schizophrenia

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Phenothiazines with piperazine structure
FDA pharmacologic class
Phenothiazine FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA37.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli37.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae15.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis66.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

34registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Perphenazine in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.2 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.0 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.1 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.5 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Perphenazine with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Efficacy and Safety of Fosaprepitant Dimeglumine in Preventing Chemotherapy-Induced Nausea and Vomiting (MK-0517-031)

    NCT01594749 · start 2012-09-24

    Registered record
    Registry ID
    NCT01594749
    Conditions
    Chemotherapy-Induced Nausea and Vomiting (CINV)
    Interventions
    Fosaprepitant dimeglumine; Fosaprepitant Placebo; Dexamethasone; Ondansetron; Dexamethasone Placebo; Ondansetron Placebo; Rescue Therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2012-09-24
    Completion
    2014-11-03
    Enrolment
    1,015

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChemotherapy-Induced Nausea and Vomiting (CINV)
    InterventionFosaprepitant dimeglumine; Fosaprepitant Placebo; Dexamethasone; Ondansetron +3 more
    PhasePhase 3
    Registry statusCompleted

  • A Randomized Double-blind Trial With 6 Antipsychotic Drugs for Schizophrenia

    NCT02192723 · start 2012-06

    Registered record
    Registry ID
    NCT02192723
    Conditions
    Schizophrenia
    Interventions
    Typical antipsychotic; Risperidone; Olanzapine; Quetiapine; Aripiprazole; Ziprasidone
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2012-06
    Completion
    2014-06
    Enrolment
    550

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    InterventionTypical antipsychotic; Risperidone; Olanzapine; Quetiapine +2 more
    PhaseNot applicable
    Registry statusCompleted

  • Antipsychotics and Risk of Hyperglycemic Emergencies

    NCT02582736 · start 2012-04

    Registered record
    Registry ID
    NCT02582736
    Conditions
    Psychotic Disorders; Schizophrenia; Schizoaffective Disorder; Bipolar Disorder; Diabetes Mellitus, Type 2
    Interventions
    Olanzapine; Risperidone; atypical antipsychotics (other); typical antipsychotics
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2012-04
    Completion
    2012-12
    Enrolment
    725,489

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPsychotic Disorders; Schizophrenia; Schizoaffective Disorder; Bipolar Disorder +1 more
    InterventionOlanzapine; Risperidone; atypical antipsychotics (other); typical antipsychotics
    PhaseNot recorded
    Registry statusCompleted

  • Phase IIb-III Study of BL-1020 Small Molecule for Schizophrenia

    NCT01363349 · start 2011-05

    Registered record
    Registry ID
    NCT01363349
    Conditions
    Schizophrenia; Cognitive Effect on Schizophrenic Patients
    Interventions
    CYP-1020; Risperidone
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Terminated
    Start
    2011-05
    Completion
    2013-04
    Enrolment
    269

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia; Cognitive Effect on Schizophrenic Patients
    InterventionCYP-1020; Risperidone
    PhasePhase 2 / Phase 3
    Registry statusTerminated

  • Correlation Between Cognitive Function and Relapse of Schizophrenia Regarding Dose Reduction

    NCT03019887 · start 2011-04

    Registered record
    Registry ID
    NCT03019887
    Conditions
    Schizophrenia Relapse
    Interventions
    reduction of risperidone, haloperidol, olanzapine, quetiapine, aripiprazole, paliperidone, levomepromazine, perphenazine
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2011-04
    Completion
    2017-01
    Enrolment
    139

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia Relapse
    Interventionreduction of risperidone, haloperidol, olanzapine, quetiapine, aripiprazole, paliperidone, levomepromazine, perphenazine
    PhaseNot applicable
    Registry statusCompleted

  • Decision Aid to Facilitate Shared Decision Making During Treatment in Schizophrenia

    NCT01420575 · start 2010-10

    Registered record
    Registry ID
    NCT01420575
    Conditions
    Schizophrenia; Schizoaffective Disorder
    Interventions
    Visual Decision Aid and Shared Decision Making Model; Usual Care
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Terminated
    Start
    2010-10
    Completion
    2012-08
    Enrolment
    8

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia; Schizoaffective Disorder
    InterventionVisual Decision Aid and Shared Decision Making Model; Usual Care
    PhaseNot applicable
    Registry statusTerminated

  • Twelve Month Study Comparing Paliperidone Palmitate and Select Oral Antipsychotics in Adults With Schizophrenia Who Have Been Recently Discharged From an Inpatient Psychiatric Hospital

    NCT01193166 · start 2010-08

    Registered record
    Registry ID
    NCT01193166
    Conditions
    Schizophrenia
    Interventions
    paliperidone palmitate; risperidone; olanzapine; aripiprazole; haloperidole; quetiapine; perphenazine; paliperidone
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Withdrawn
    Start
    2010-08
    Completion
    2012-09
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    Interventionpaliperidone palmitate; risperidone; olanzapine; aripiprazole +4 more
    PhasePhase 4
    Registry statusWithdrawn

  • 15 Month Study for Adults Who Have Been Diagnosed With Schizophrenia and Incarcerated

    NCT01157351 · start 2010-05

    Registered record
    Registry ID
    NCT01157351
    Conditions
    Schizophrenia
    Interventions
    paliperidone; risperidone; haloperidole; perphenazine; aripiprazole; quetiapine; paliperidone palmitate; olanzapine
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2010-05
    Completion
    2013-12
    Enrolment
    450

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    Interventionpaliperidone; risperidone; haloperidole; perphenazine +4 more
    PhasePhase 4
    Registry statusCompleted

  • Reducing Antipsychotic-Induced Weight Gain in Children With Metformin

    NCT01231074 · start 2010-02

    Registered record
    Registry ID
    NCT01231074
    Conditions
    Obesity; Weight Gain; Psychotropic Induced Weight Gain
    Interventions
    Metformin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2010-02
    Completion
    2013-05
    Enrolment
    96

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionObesity; Weight Gain; Psychotropic Induced Weight Gain
    InterventionMetformin
    PhasePhase 1
    Registry statusCompleted

  • Reducing Weight Gain and Improving Metabolic Function in Children Being Treated With Antipsychotics

    NCT00806234 · start 2009-01

    Registered record
    Registry ID
    NCT00806234
    Conditions
    Psychotic Disorders
    Interventions
    Aripiprazole or Perphenazine; Metformin; Olanzapine, quetiapine, risperidone, ziprasidone, aripiprazole, asenapine, iloperidone, lurasidone, paliperidone, or olanzapine/fluoxetine
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2009-01
    Completion
    2014-03
    Enrolment
    127

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPsychotic Disorders
    InterventionAripiprazole or Perphenazine; Metformin; Olanzapine, quetiapine, risperidone, ziprasidone, aripiprazole, asenapine, iloperidone, lurasidone, paliperidone, or olanzapine/fluoxetine
    PhasePhase 4
    Registry statusCompleted

  • Comparison of Optimal Antipsychotic Treatments for Adults With Schizophrenia

    NCT00802100 · start 2008-12

    Registered record
    Registry ID
    NCT00802100
    Conditions
    Schizophrenia
    Interventions
    Olanzapine; Perphenazine; Aripiprazole; Metformin; Simvastatin; Benztropine
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2008-12
    Completion
    2009-10
    Enrolment
    21

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    InterventionOlanzapine; Perphenazine; Aripiprazole; Metformin +2 more
    PhasePhase 4
    Registry statusCompleted

  • A Double-Blind, Controlled Study of Aripiprazole in Co-Morbid Schizophrenia and Cocaine Dependence

    NCT00737256 · start 2008-08

    Registered record
    Registry ID
    NCT00737256
    Conditions
    Schizophrenia; Cocaine Dependence
    Interventions
    Aripiprazole; Perphenazine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2008-08
    Completion
    2014-05
    Enrolment
    44

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia; Cocaine Dependence
    InterventionAripiprazole; Perphenazine
    PhasePhase 2
    Registry statusUnknown

  • A Six-week, Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-center, Phase II Study

    NCT00567710 · start 2008-07

    Registered record
    Registry ID
    NCT00567710
    Conditions
    Schizophrenia
    Interventions
    BL - 1020; BL - 1020; Placebo; Risperidone
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2008-07
    Completion
    2009-09
    Enrolment
    360

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    InterventionBL - 1020; BL - 1020; Placebo; Risperidone
    PhasePhase 2
    Registry statusCompleted

  • Extension Study To Evaluate The Long-Term Safety, Tolerability, And Efficacy Of Low And High Doses Of Bl-1020

    NCT00722176 · start 2008-06

    Registered record
    Registry ID
    NCT00722176
    Conditions
    Schizophrenia
    Interventions
    BL-1020; BL-1020 10-30 mg; risperidone
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2008-06
    Completion
    2009-12
    Enrolment
    220

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    InterventionBL-1020; BL-1020 10-30 mg; risperidone
    PhasePhase 2
    Registry statusCompleted

  • Safety and Tolerability of BL-1020 in Hospitalized Subjects With Chronic Schizophrenia or Schizo-Affective Disorder

    NCT00480571 · start 2007-06

    Registered record
    Registry ID
    NCT00480571
    Conditions
    Schizophrenia; Schizoaffective Disorder
    Interventions
    BL-1020; BL 1020 High Dose
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2007-06
    Completion
    2007-12
    Enrolment
    90

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia; Schizoaffective Disorder
    InterventionBL-1020; BL 1020 High Dose
    PhasePhase 2
    Registry statusCompleted